Intra-Cellular Therapies
ITCI
Market cap $8.31B

78.68 USD

+2.59

3.40%

At close Oct 17, 4:00 PM EDT

After hours

78.68

+0.00

0.00%

1 day

3.40%

5 days

6.76%

1 month

4.75%

3 months

2.84%

6 months

2.59%

Year to date

11.62%

1 year

46.90%

5 years

825.65%

About: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Employees: 561

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 13 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

73% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 44

12% more repeat investments, than reductions

Existing positions increased: 140 | Existing positions reduced: 125

10% more funds holding

Funds holding: 336 [Q1] → 368 (+32) [Q2]

8% more capital invested

Capital invested by funds: $6.08B [Q1] → $6.6B (+$514M) [Q2]

9% more call options, than puts

Call options by funds: $28.9M | Put options by funds: $26.5M

0.38% more ownership

Funds ownership: 90.87% [Q1] → 91.25% (+0.38%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$74

6%

downside

Avg. target

$102

30%

upside

High target

$130

65%

upside

13 analyst ratings

11 positive

85%

2 neutral

15%

0 negative

0%

Morgan Stanley Jeffrey Hung 50% 1-year accuracy 11 / 22 met price target	21%upside $95	Overweight Maintained	11 Oct 2024
RBC Capital Brian Abrahams 44% 1-year accuracy 33 / 75 met price target	37%upside $108	Outperform Maintained	4 Oct 2024
Cantor Fitzgerald Charles Duncan 45% 1-year accuracy 31 / 69 met price target	65%upside $130	Overweight Reiterated	20 Sept 2024
Cantor Fitzgerald Charles Duncan 45% 1-year accuracy 31 / 69 met price target	65%upside $130	Overweight Reiterated	16 Sept 2024
Piper Sandler Charles Duncan 45% 1-year accuracy 31 / 69 met price target	17%upside $92	Overweight Upgraded	6 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ITCI published over the past 30 days

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024.

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

Zacks Investment Research

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Zacks Investment Research

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

Investors Business Daily

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon

This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon

Zacks Investment Research

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications & Investor Relations Sharon Mates - Founder, Chairman & Chief Executive Officer Mark Neumann - Executive Vice President & Chief Commercial Officer Lawrence Hineline - Senior Vice President of Finance & Chief Financial Officer Suresh Durgam - Executive Vice President & Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Brian Abrahams - RBC Capital Markets Dina Ramadane - Bank of America Securities Charles Duncan - Cantor Fitzgerald Marc Goodman - Leerink Partners Michael DiFiore - Evercore ISI Jeff Hung - Morgan Stanley Ami Fadia - Needham & Company Joseph Thome - TD Cowen Graig Suvannavejh - Mizuho Securities Joel Beatty - Baird David Amsellem - Piper Sandler Operator Good morning ladies and gentlemen and welcome to Intra-Cellular Therapies Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.45 per share a year ago.

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™